Comparing Combination Treatment Regimens in Transplant-Eligible NDMM

Video

Matthew James Pianko, MD, provides an overview of the recently updated data from the GRIFFIN trial and the role of quadruplet versus triplet regimens in the treatment landscape of transplant-eligible newly diagnosed multiple myeloma.

Recent Videos
4 experts in this video
4 experts in this video
4 experts in this video
4 experts in this video
4 experts in this video
Andrezj Jakubowiak, MD, PhD, prioritizes KRd-based regimens for the treatment of high-risk newly diagnosed disease in the post-transplant setting.
Although a similar proportion achieved MRD negativity at the 10 to the –6 power, not enough studies have analyzed MRD at this level for multiple myeloma.
Unique toxicities presented with talquetamab tend to get progressively better as the treatment course continues, according to Prerna Mewawalla, MD.
Related Content
Two belantamab mafodotin regimens have been approved in multiple myeloma despite the FDA’s ODAC committee voting against the proposed dosages due to ocular toxicities.

FDA Approves Belantamab Mafodotin in R/R Multiple Myeloma

Tim Cortese
October 23rd 2025
Article

Belantamab mafodotin has been approved for multiple myeloma despite the FDA’s ODAC committee voting against the treatment due to ocular toxicities.

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025
Podcast

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

The safety profile of venetoclax combined with bortezomib and dexamethasone was consistent with previously published results.

Venetoclax Combo Achieves Mixed Results in Relapsed/Refractory Multiple Myeloma

Tim Cortese
October 17th 2025
Article

Venetoclax with bortezomib and dexamethasone led to a median PFS of 23.4 months compared with 11.4 months with placebo in patients with R/R MM.

Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

Mitigating AEs and Protecting QOL Following Talquetamab in Multiple Myeloma

Samantha Shenoy, NP, MSN
October 14th 2024
Podcast

Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

The addition of comprehensive bridging radiotherapy to extramedullary disease sites before CAR T therapy may improve PFS outcomes in multiple myeloma.

Bridging Radiotherapy Prior to CAR T May Be Safe in R/R Multiple Myeloma

Roman Fabbricatore
October 13th 2025
Article

The addition of comprehensive bridging radiotherapy to extramedullary disease sites before CAR T therapy may improve PFS outcomes in multiple myeloma.

The most common any-grade AE was diarrhea, occurring in 74.0% of the experimental group and 72.2% of the standard group.

Antiemetic Regimen Limits Chemo-Induced Nausea/Vomiting in Multiple Myeloma

Tim Cortese
October 6th 2025
Article

Patients with multiple myeloma who received palonosetron, dexamethasone, aprepitant, and olanzapine achieved a 44.1% CR rate across all study phases.